Miami (PRWEB) March 10, 2016
The First Inter American Regenerative and Cellular Medicine Conference (http://www.regenestemconference.com), an international showcase of the latest innovations and best practices in the field of regenerative medicine and cellular therapies, has named several of the prominent speakers for this year’s event to be held in Cuba.
The inaugural conference will take place October 13-15, at the Palacio de Convenciones, in Havana.
The First Inter American Regenerative and Cellular Medicine Conference is being presented by Regenestem, LLC (http://www.regenestem.com), in association with the Cuban Institute of Hematology and Immunology, The Cuban Society of Hematology, and The Cuban Ministry of Health.
Regenestem is a medical practice firm based in the U.S. that focuses on adult stem cell therapies and physician training, with particular growth in Latin America.
To date, the roster of prominent physicians who will speak at the October conference includes:
- Arnold I. Caplan, PhD - Professor of Biology and Director of the Skeletal Research Center at Case Western Reserve University (Cleveland, OH). Known as the “Father of the Mesenchymal Stem Cell (MSC).”
- Anthony Atala, M.D. - W.H. Boyce Professor and Director of the Wake Forest Institute for Regenerative Medicine and Chair of the Department of Urology at Wake Forest University School of Medicine (Winston-Salem, NC). Recipient: Christopher Columbus Foundation Award, bestowed on a living American who is currently working on a discovery that will significantly affect society, along with many other prestigious awards in medicine.
- Rocky S. Tuan, PhD – Director, Cellular and Molecular Engineering Lab; Professor and Executive Vice Chairman for Orthopaedic Research; Arthur J. Rooney, Sr. Chair Professor in Sports Medicine; Department of Orthopaedic Surgery, University of Pittsburgh.
- Joshua M. Hare, M.D. - Chief of the Division of Cardiology; Louis Lemberg Professor of Medicine; Professor of Molecular and Cellular Pharmacology; Director of the Interdisciplinary Stem Cell Institute; University of Miami Miller School of Medicine.
- Robert M. Nerem, PhD – Parker H. Petit Distinguished Chair for Engineering in Medicine and Institute Professor Emeritus; Founding Director of the Parker H. Petit Institute for Bioengineering and Bioscience; Georgia Institute of Technology (Atlanta).
- Jakub Tolar, MD, PhD - Distinguished McKnight Professor, Blood and Marrow Transplantation, Department of Pediatrics; Tulloch Chair in Stem Cell Biology, Genetics and Genomics; Director, Stem Cell Institute; University of Minnesota.
- Sydney R. Coleman, MD - Clinical Assistant Professor, Hansjorg Wyss Department of Plastic Surgery, New York University.
- Vasilis Paspaliaris, MD, PhD – President at Tithon Biotech, Inc. Founder and Director of Adistem, Ltd. Received an appreciation award in 2008 from the American Association of Clinical Endocrinologists for his groundbreaking work on adipose-derived stem cells in Type II diabetic patients. Knighted by the Greek Orthodox Church for his humanitarian accomplishments.
The three-day conference will address specific issues involving the process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function. In addition, the program will present clinical applications for adult stem cell therapies and explore whether they are ready to become a standard form of treatment.
Among the topics to be covered by the speakers and during hands-on training workshops include adult stem cells derived from adipose tissue, bone marrow and the use of growth factors, as well as the use of platelets and platelet components and obtaining pluripotent stem cells and growth factors for use in various therapies.
The conference will also provide exhibition space where the leading vendors and product suppliers in the industry will demonstrate their latest offerings for those in attendance.
For more information or to register, go to http://www.regenestemconference.com or call (305) 224-1858. Registrations and travel arrangements must be made by July 1.